These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12773042)

  • 21. Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.
    Groneberg RD; Burns CJ; Morrissette MM; Ullrich JW; Morris RL; Darnbrough S; Djuric SW; Condon SM; McGeehan GM; Labaudiniere R; Neuenschwander K; Scotese AC; Kline JA
    J Med Chem; 1999 Feb; 42(4):541-4. PubMed ID: 10052961
    [No Abstract]   [Full Text] [Related]  

  • 22. The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.
    Levin JI; Chen JM; Du MT; Nelson FC; Wehr T; DiJoseph JF; Killar LM; Skala S; Sung A; Sharr MA; Roth CE; Jin G; Cowling R; Di L; Sherman M; Xu ZB; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2975-8. PubMed ID: 11677139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.
    Xue CB; Chen XT; He X; Roderick J; Corbett RL; Ghavimi B; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Trzaskos J; Newton RC; Duan JJ; Decicco CP
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4453-9. PubMed ID: 15357971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.
    Duan JJ; Chen L; Lu Z; Xue CB; Liu RQ; Covington MB; Qian M; Wasserman ZR; Vaddi K; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    Bioorg Med Chem Lett; 2008 Jan; 18(1):241-6. PubMed ID: 18032037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
    Scozzafava A; Supuran CT
    J Med Chem; 2000 Oct; 43(20):3677-87. PubMed ID: 11020282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
    Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
    Sawa M; Kiyoi T; Kurokawa K; Kumihara H; Yamamoto M; Miyasaka T; Ito Y; Hirayama R; Inoue T; Kirii Y; Nishiwaki E; Ohmoto H; Maeda Y; Ishibushi E; Inoue Y; Yoshino K; Kondo H
    J Med Chem; 2002 Feb; 45(4):919-29. PubMed ID: 11831904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
    Hanessian S; Bouzbouz S; Boudon A; Tucker GC; Peyroulan D
    Bioorg Med Chem Lett; 1999 Jun; 9(12):1691-6. PubMed ID: 10397503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors.
    Rush TS; Powers R
    Curr Top Med Chem; 2004; 4(12):1311-27. PubMed ID: 15320728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
    Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
    Hanessian S; Moitessier N; Gauchet C; Viau M
    J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.
    Natchus MG; Bookland RG; De B; Almstead NG; Pikul S; Janusz MJ; Heitmeyer SA; Hookfin EB; Hsieh LC; Dowty ME; Dietsch CR; Patel VS; Garver SM; Gu F; Pokross ME; Mieling GE; Baker TR; Foltz DJ; Peng SX; Bornes DM; Strojnowski MJ; Taiwo YO
    J Med Chem; 2000 Dec; 43(26):4948-63. PubMed ID: 11150165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
    Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
    Barlaam B; Bird TG; Lambert-Van Der Brempt C; Campbell D; Foster SJ; Maciewicz R
    J Med Chem; 1999 Nov; 42(23):4890-908. PubMed ID: 10579851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the inhibition of other metalloproteinases by matrix metalloproteinase inhibitors.
    Marcotte PA; Elmore IN; Guan Z; Magoc TJ; Albert DH; Morgand DW; Curtin ML; Garland RB; Guo Y; Heyman HR; Holms JH; Sheppard GS; Steinman DH; Wada CK; Davidsen SK
    J Enzyme Inhib; 1999; 14(6):425-35. PubMed ID: 10536876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
    Pratt LM; Beckett RP; Bellamy CL; Corkill DJ; Cossins J; Courtney PF; Davies SJ; Davidson AH; Drummond AH; Helfrich K; Lewis CN; Mangan M; Martin FM; Miller K; Nayee P; Ricketts ML; Thomas W; Todd RS; Whittaker M
    Bioorg Med Chem Lett; 1998 Jun; 8(11):1359-64. PubMed ID: 9871766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
    Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
    Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
    Hanessian S; MacKay DB; Moitessier N
    J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.